Quick Answer
COGNITION THERAPEUTICS INC reported R&D Expense of $37.19 million for fiscal year 2025.
COGNITION THERAPEUTICS INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $37.19M | -10.8% |
| 2024 | $41.68M | +12.0% |
| 2023 | $37.20M | +22.7% |
| 2022 | $30.32M | +63.3% |
| 2021 | $18.57M | +44.1% |
| 2020 | $12.89M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.77M | -66.9% | -67.1% |
| June 30, 2025 | $11.48M | -0.8% | +6.4% |
| March 31, 2025 | $10.79M | +2.2% | -5.3% |
| September 30, 2024 | $11.39M | -2.4% | -1.6% |
| June 30, 2024 | $11.58M | +36.2% | +9.7% |
| March 31, 2024 | $10.55M | +94.3% | -9.6% |
| September 30, 2023 | $11.67M | +41.1% | +37.3% |
| June 30, 2023 | $8.50M | -6.6% | +56.5% |
- COGNITION THERAPEUTICS INC showed a decrease of -10.8% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, COGNITION THERAPEUTICS INC’s r&d expense has grown by 188.6% (from $12.89 million to $37.19 million).
- The most recent figure is from COGNITION THERAPEUTICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: